

SVEBIO – workshop , Stockholm, 8 april 2019 Alexander Schenk



The EIB Group



The lending arm of the European Union since 1958.




Specialist provider of risk finance to small and medium-sized enterprises.





The EIB: capital breakdown

As at 31 December 2018






The EIB at a glance

- Largest multilateral lender and borrower in the world
 - We raise our funds on the international capital markets
 - We pass on favourable borrowing conditions to clients
- In 60 years, over € 1.2tn invested
 - More than 12 000 projects in over 160 countries
 - Crowding-in bank: mobilising up to € 3tn of overall investment
- Headquartered in Luxembourg
 - Around 3 400 staff: In addition to finance professionals, there are engineers, economists and socio-environmental experts
 - 50 local offices around the world




EIB financing since its foundation







EIB Group-supported investment





We deliver impact where it is needed



JOBS

5 million jobs in small businesses



TRANSPORT

290 million additional passengers



HEALTH

27.3 million people with access to improved health services



ENERGY

34.3 million households powered by EIB projects



WATER

20 million people benefiting from safer drinking water



DIGITAL

29 million people with new or upgraded connections



Our priorities

Innovation



Infrastructure

SMEs







€ **15.**2bn




€ **12.**3bn




€ 23.3bn







11




Raising money on the capital markets

Borrowing in 2018

€ 60_{bn}

Largest issuer of **Green** bonds





EIB products help catalyse investment

While each of our transactions is tailor-made to meet the needs of the project, our products are generally classified into loans, guarantees, equity investments and advisory services. These can be combined, or 'blended' with other sources of public financing.






EIB project cycle

We support sound and sustainable projects





European Fund for Strategic Investments (EFSI)





European Fund for Strategic Investments to 2018

Approved operations

1031

EFSI financing approved

€ 70.4bn

Supporting total investment of

€ 375.5bn



Situation as at 31 December 2018



A responsible bank

Corporate responsibility is part of all of our activities

- We appraise and monitor the environmental and social sustainability of all of our investment projects.
- Our appraisals take account of all resources used by the project, whether human, technological or natural, to determine whether society at large gains from the investment.
- Certain economic activities are completely excluded from EIB financing.
- We apply our carbon footprint methodology to report the greenhouse gas emissions from all projects with significant impact.
- We continuously monitor, report on, and take action to reduce our own internal environmental footprint.
- We are committed to ensuring strong governance, transparency and accountability, for us and our counterparts.



Investments in Biofuels

- ABF Biofuel Production (2007)
 Construction of two bioethanol production plants
 EUR 167 million
- Biofuel Plant Poland (2010) Construction of bioethanol plant near Nysa EUR 20 million
- Chemtex Second generation biofuels RDI (2013) RDI investments to develop second generation biofuels EUR 60 million
- Mauritius Ethanol Project (2013)
 Ethanol plant for biofuel from molasses
 EUR 8 million





InnovFin

EU Finance for Innovators

Midcaps	Large Caps	Thematic Finance	Advisory
InnovFin MidCap Guarantee	InnoVFin Large Projects	InnovFin Energy Demo Projects	Inno√Fin Advisory
InnovFin MidCap Growth Finance		InnovFin Infectious Diseases	
	Large Caps	SPV, Midcaps and	Public and Private Sector
Midcaps < 3 000 Employees	Typically > 3 000 Employees	Large Caps	Promoters Promoters



Thematic Financing

Energy Demo Projects

 Financing between EUR 7,5m and EUR 75m for firstof-a-kind demonstration projects for new technologies which are ready for demonstration at scale

Infectious Diseases

 Financing between EUR 7,5m and EUR 75m for devoloping vaccines, drugs, medical and diagnostic devices, and research infrastructure for combatting infectious diseases





Head of Office

European Investment Bank Stockholm Office Östermalmstorg 1, 4e våningen 11442 Stockholm

a.schenk@eib.org





European Investment Bank 98-100, boulevard Konrad Adenauer L-2950 Luxembourg

www.eib.org